Metraipolis › archive › dc_fd434808ddd4
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis — Europe PMC PMID:41992489
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41992489
- DOI
- 10.1093/oncolo/oyag137
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-07T22:58:08.744Z
- SHA-256 of the archived text
ced6dc66f88b99edc4c56a666a0aa9069b6353fdeb8ac6df7f7b6941cc11b431- Stable URL of this page
https://metraipolis.com/documento/dc_fd434808ddd4
How to cite
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis — Europe PMC PMID:41992489 — Europe PMC (en), https://europepmc.org/article/MED/41992489 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fd434808ddd4 (Metraipolis archive dc_fd434808ddd4, sha256 ced6dc66f88b99edc4c56a666a0aa9069b6353fdeb8ac6df7f7b6941cc11b431)
BibTeX
@misc{dcfd434808ddd4,
title = {Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysis — Europe PMC PMID:41992489},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41992489},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fd434808ddd4; sha256 ced6dc66f88b99edc4c56a666a0aa9069b6353fdeb8ac6df7f7b6941cc11b431},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41992489. Agents can read the archived copy with the MCP tool read_document.